Modification of κ-opioid receptor agonist-induced antinociception by diabetes in the mouse brain and spinal cord

Journal of Pharmacological Sciences

Volumn 98, Issue 1, 2005, Pages 25-32

  Ohsawa, Masahiro ^a,b   Kamei, Junzo ^a  

^a HOSHI UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Antinociception; Diabetes; TRK 820; opioid receptor

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; ENADOLINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA1 OPIATE RECEPTOR AGONIST; KAPPA2 OPIATE RECEPTOR; KAPPA3 OPIATE RECEPTOR; NALFURAFINE; R 84760; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG RESPONSE; MALE; MOUSE; NONHUMAN; PAIN; RECEPTOR AFFINITY; SPINAL CORD; TAIL FLICK TEST;

EID: 20444376975     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040621     Document Type: Article

References (33)

1. Andrew JH, Mannes J, Dubner R, Caudle RM. Putative kappa-2 opioid agonists are antihyperalgesic in rat model of inflammation. J Pharmacol Exp Ther. 1997;281:136-141.
2. Endoh T, Tajima A, Suzuki T, Kamei J, Suzuki T, Narita M, et al. Characterization of the antinociceptive effects of TRK-820 in the rat. Eur J Pharmacol. 2000;387:133-140.
3. Mori T, Nomura M, Nagase H, Narita M, Suzuki T. Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology. 2002;161:17-22.
4. Ohnishi A, Mihara M, Yasuda S, Tomono Y, Hasegawa J, Tanaka T. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J Pharmacol Exp Ther. 1994;270:342-347.
5. King AC, Ho A, Schluger J, Borg L, Kreek MJ. Acute subjective effects of dynorphine A(1-13) infusion in normal healthy subjects. Drug Alcohol Depend. 1999;54:87-90.
6. Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther. 1999;288:260-269.
7. Zukin RS, Eghbali M, Olive D, Unterwald EM, Temnel A. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc Natl Acad Sci USA. 1988;85:4061-4065.
8. Butelma ER, Ko MC, Sobczyk-Kojiro K, Mosberg HI, Van Bemmel B, Zerning G, et al. Kappa-opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. J Pharmacol Exp Ther. 1998;285:595-601.
9. Caudle RM, Finegold AA, Mannes AJ, Tobias MD, Kenshalo DR Jr, Iadarola MJ. Spinal kappa1 and kappa2 opioid binding sites in rats, guinea pigs, monkeys and humans. NeuroReport. 1998;9:2523-2525.
10. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, et al. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol Pharmacol. 1994;45:330-334.
11. Clark JA, Liu L, Price M, Hersh B, Edelson M, Pasternak GW. Kappa opiate receptor multiplicity: evidence for two U-50,488H-sensitive kappa1 subtypes and a novel kappa3 subtype. J Pharmacol Exp Ther. 1989;251:461-468.
12. Cheng J, Roques BP, Gacel GA, Huang P, Pasternak GW. Kappa 3 opiate receptor binding in the mouse and rat. Eur J Pharmacol. 1992;226:15-20.
13. Nagase H, Hayakawa J, Kawamura K, Kawai K, Takezawa Y, Matsuura H, et al. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull. 1998;46:366-369.
14. Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, et al. Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist. Life Sci. 1999;65:1685-1694.
15. Tsuji M, Takeda H, Matsumiya T, Nagase H, Yamazaki M, Narita M, et al. A novel κ-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci. 2000;66:PL353-PL358.
16. Kamei J, Kasuya Y. The effects of diabetes on opioid-induced antinociception. In: Tseng LF, editor. The pharmacology of opioid peptides. Chur, Switzerland: Harwood Academic Publishers; 1995. p. 271-301.
17. 2-opioid receptors. Neurosci Lett. 1994;165:141-143.
18. 2-opioid receptors. Life Sci. 1994; 55:PL121-PL126.
19. Haley MJ, McCormick WG. Pharmacological effects produced by intracerebral injections of drug in the conscious mice. Br J Pharmacol. 1957;12:12-15.
20. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 1980;67:313-316.
21. Costello GF, Main BG, Barlow JJ, Carroll JA, Shaw JS. A novel series of potent and selective agonists at the opioid kappa-receptor. Eur J Pharmacol. 1988;151:475-478.
22. Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC, et al. CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol. 1990;101:183-189.
23. Fujibayashi K, Sakamoto K, Watanabe M, Iizuka Y. Pharmacological properties of R-84760, a novel κ-opioid receptor agonist. Eur J Pharmacol. 1994;261:133-140.
24. Finney DJ. Statistical Methods in Biological Assays. 2nd ed. Haffner Publishing; 1964.
25. Tallarida RJ, Porreca F, Cowan A. Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 1989;45:947-961.
26. Seki T, Awamura S, Kimura C, Ide S, Sakano K, Minami M, et al. Pharmacological properties of TRK-820 on cloned μ-, δ-and κ-opioid receptors and nociceptin receptor. Eur J Pharmacol. 1999;376:159-167.
27. 3-opioid receptor?: the endogenous heptadecapeptide, nociceptin, reveals that the KOR3 clone may not be an orphan receptor. Trends Pharmacol Sci. 1996;17:217.
28. Pan Y-X, Xu J, Mahurter L, Bolan E, Xu M, Pasternak GW. Generation of the mu opioid receptor (MOR-1) protein by three new splice bariants of the Oprm gene. Proc Natl Acad Sci USA. 2001;98:14084-14089.
29. Paul D, Bodnar RJ, Gistrak MA, Pasternak GW. Different m receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol. 1989;168:307-314.
30. Gavériaux-Ruff C, Peluso J, Befort K, Simonin F, Zilliox C, Kieffer BL. Detection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the δ- and κ-opioid receptors. Mol Brain Res. 1997;48:298-304.
31. Pasternak KR, Rossi GC, Zuckerman A, Pasternak GW. Antisense mapping KOR-1: evidence for multiple kappa analgesic mechanisms. Eur J Pharmacol. 1999;826:289-292.
32. Kamei J, Kawashima N, Kasuya Y. Serum glucose level-dependent and independent modulation of μ-opioid agonist-mediated analgesia in diabetic mice. Life Sci. 1993;52:53-60.
33. Kamei J, Kawashima N, Kasuya Y. Role of spleen or spleen products in the deficiency in morphine induced analgesia in diabetic mice. Brain Res. 1992;576:139-142.